Brain Tumour Group,Breast Cancer Group,Cancer in Elderly Task Force,Gastrointestinal Tract Cancer Group,Lung Cancer Group,News,Radiation Oncology Group,Soft Tissue and Bone Sarcoma Group,Uncategorized
EORTC Abstracts at ASCO 2013 in Chicago
16 May 2013
The EORTC will present thirteen abstracts at the ASCO 2013 Annual Meeting which will be held 31 May – 04 June 2013 in Chicago, Illinois. All thirteen of the EORTC’s submitted abstracts were accepted for presentation: four abstracts will be presented in Oral Abstract Sessions, one in a Clinical Science Symposium, two in Poster Discussion Sessions, and five in General Poster Sessions. Full texts of these abstracts are available on the ASCO 2013 website.
Oral Abstract Session
Abstract # LBA2009
Roger Stupp, Monika E. Hegi, Thierry Gorlia, Sara Erridge, Danica Grujicic, Joachim Peter Steinbach, Wolfgang Wick, Rafal Tarnawski, Do-Hyun Nam, Astrid Weyerbrock, Peter Hau, Martin JB Taphoorn, Louis B. Nabors, David A. Reardon, Martin J. Van Den Bent, James R. Perry, Yong Kil Hong, Christine Hicking, Martin Picard, and Michael Weller
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III centric study
Abstract # LBA1001
Emiel J. Rutgers, Mila Donker, Marieke Evelien Straver, Philip Meijnen, Cornelis J. H. Van De Velde, Robert E. Mansel, Helen Westenberg, Lorenzo Orzalesi, Willem H. Bouma, Huub van der Mijle, Grard A. P. Nieuwenhuijzen, Sanne C. Veltkamp, Leen Slaets, Carlo G. M. Messina, Nicole J. Duez, Coen Hurkmans, Jan Bogaerts, and Geertjan van Tienhoven
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023)
Abstract # 2007
Brigitta G Baumert, Warren P. Mason, Gail Ryan, Jacoline E Bromberg, Martin J. Van Den Bent, Khê Hoang-Xuan, Alba Ariela Brandes, Guy Kantor, Martin JB Taphoorn, Mohamed Ben Hassel, Jeremy Rees, Wolfgang Wick, Andreas Von Deimling, Christian Hartmann, Johan M Kros, Monika E. Hegi, Nicolas Dif, Denis A. Lacombe, Thierry Gorlia, and Roger Stupp
Temozolomide chemotherapy vs. radiotherapy in molecularly characterized (1p loss) low-grade glioma. a randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)
Abstract # 10500
Paolo Giovanni Casali, Axel Le Cesne, Andres Poveda Velasco, Dusan Kotasek, Piotr Rutkowski, Peter Hohenberger, Elena Fumagalli, Ian Robert Judson, Antoine Italiano, Javier Martin Broto, Alessandro Gronchi, Angelo Paolo Dei Tos, Sandrine Marreaud, Winette T.A. Van Der Graaf, John Raymond Zalcberg, Saskia Litière, Jean-Yves Blay, EORTC Soft Tissue and Bone Sarcoma Group (EORTC STBSG), French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Grupo Español de Investigación en Sarcomas (GEIS), and Australasian Gastro-Intestinal Trials Group (AGITG)
Imatinib failure-free survival in patients with localized gastrointestinal stromal tumors treated with adjuvant imatinib: the EORTC/AGITG/FSG/GEIS/ISG randomized controlled Phase III trial
Clinical Science Symposium
Abstract # 2011
Martin J Van Den Bent, Lale Erdem, Thierry Gorlia, Martin JB Taphoorn, Johan M Kros, Pieter Wesseling, Anouk Allgeier, Hendrikus J Dubbink, Ahmed Idbaih, Marc Sanson, and Pim French
Optimizing the identification of anaplastic oligodendroglioma patients that benefit from adjuvant PCV chemotherapy using the illumina platform: A further report from EORTC study 26951
Poster Discussion Session
Abstract # 4529
Sandra Collette, R Sylvester, J Bellmunt, G Mead, JM Kerst, M Leahy, P Maroto, T Gil, S Marreaud, G Daugaard, I Skoneczna, R de Wit, and M De Santis
Prognostics factors in previously untreated urothelial cancer patients ineligible for Cisplatin based chemotherapy: an external validation of the Bajorin risk groups
Abstract # 3531
Hans Joachim Schmoll, K Haustermans, T Price, B Nordlinger, RD Hofheinz, J-F Daisne, J Janssens, B Brenner, P Schmidt, H Reinel, S Hollerbach, K Caca, F Fauth, CV Hannig, J Zalcberg, N Tebbutt, ME Mauer, C Messina, M Lutz, and E Van Cutsem
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial
General Poster Session
Abstract # 7585
Rabab Mohamed Gaafar, Sanjay Popat, Jan P. Van Meerbeeck, Paul Baas, Dean Fennell, Athanasios G. Pallis, Baktiar Hasan, and Mary O’Brien
Platelet counts at baseline and on treatment as predictor for progression free survival in patients with advanced malignant pleural mesothelioma: EORTC 08052 study
Abstract # 7584
Baktiar Hasan, Athanasios G. Pallis, Rabab Mohamed Gaafar, Laurent Greillier, Jan P. Van Meerbeeck, and Mary O’Brien
Independent validation of progression free survival rate at 9 and 18 weeks as predictor for overall survival in patients with malignant pleural mesothelioma: EORTC 08052 study
Abstract # 10573
Agnieszka Wozniak, EAC Wiemer, H Burger, J Allemeersch, R van Eijsden, RHJ Mathijssen, S Sleijfer, M Smid, G Floris, R Sciot, S Marreaud, A Nzokirantevye, C Hayward, J Simon, and P Schöffski
Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052
Abstract # 10553
Bernd Kasper, Saskia Litière, Sandrine Marreaud, Stefan Sleijfer, Jaap Verweij, Sebastian Bauer, Jan M. Kerst, and Winette T.A. Van Der Graaf
Long term responders and survivors on pazopanib for soft tissue sarcomas. Subanalysis of two EORTC clinical trials 62043 and 62072
Abstract # 587
Caroline Drukker, Marjanka Schmidt, Emiel J. Rutgers, Fatima Cardoso, Karla Kerlikowske, Laura Esserman, Leen Slaets, Jan Bogaerts, and Laura J. van ‘t Veer
Breast cancer screening: Biology of tumors detected by analog and digital mammography
Abstract # 3525
Julien Taieb, Josep Tabernero, Enrico Mini, Fabien Subtil, Gunnar Folprecht, Jean-Luc Van Laethem, Joseph Thaler, John Bridgewater, Evaristo Sanches, Lone Nørgård Petersen, Laurence Collette, Eric Van Cutsem, Karine Le Malicot, Philippe Rougier, Ramon Salazar, Laurent Bedenne, Jean-François Emile, Pierre Laurent-Puig, and Come Lepage
Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab in resected stage III colon cancer
For more information concerning EORTC trials, please contact: www.eortc.org/contact
John Bean, PhD
EORTC, Medical Science Writer
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023